tiprankstipranks
Trending News
More News >
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA
US Market

Centessa Pharmaceuticals (CNTA) Stock Forecast & Price Target

Compare
153 Followers
See the Price Targets and Ratings of:

CNTA Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Centessa
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CNTA Stock 12 Month Forecast

Average Price Target

$32.57
▲(129.37%Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Centessa Pharmaceuticals in the last 3 months. The average price target is $32.57 with a high forecast of $38.00 and a low forecast of $27.00. The average price target represents a 129.37% change from the last price of $14.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","15":"$15","23":"$23","31":"$31","39":"$39"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,15,23,31,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.41,15.301538461538462,17.193076923076923,19.084615384615386,20.976153846153846,22.86769230769231,24.75923076923077,26.65076923076923,28.542307692307695,30.433846153846154,32.32538461538462,34.21692307692308,36.10846153846154,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.41,14.883846153846154,16.357692307692307,17.83153846153846,19.305384615384614,20.779230769230768,22.253076923076925,23.72692307692308,25.200769230769232,26.674615384615386,28.14846153846154,29.622307692307693,31.096153846153847,{"y":32.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.41,14.455384615384615,15.500769230769231,16.546153846153846,17.591538461538462,18.636923076923075,19.682307692307692,20.72769230769231,21.77307692307692,22.818461538461538,23.863846153846154,24.909230769230767,25.954615384615384,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.08,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$38.00Average Price Target$32.57Lowest Price Target$27.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on CNTA
Stacy KuTD Cowen
TD Cowen
Buy
Reiterated
06/17/25
TD Cowen Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA)
Leerink Partners Analyst forecast on CNTA
David RisingerLeerink Partners
Leerink Partners
$36
Buy
153.52%
Upside
Reiterated
06/09/25
Leerink Partners Remains a Buy on Centessa Pharmaceuticals (CNTA)
Jefferies Analyst forecast on CNTA
Kelly ShiJefferies
Jefferies
$27
Buy
90.14%
Upside
Reiterated
06/04/25
Centessa Pharmaceuticals: Promising Orexin Drug Pipeline and Strong Market Potential Drive Buy Rating
Needham Analyst forecast on CNTA
Ami FadiaNeedham
Needham
$35
Buy
146.48%
Upside
Initiated
05/28/25
Positive Outlook on Centessa Pharmaceuticals Driven by ORX750's Promising Potential and Market Growth
Piper Sandler Analyst forecast on CNTA
Biren AminPiper Sandler
Piper Sandler
$38
Buy
167.61%
Upside
Reiterated
05/20/25
Centessa Pharmaceuticals (CNTA) Receives a Buy from Piper Sandler
Morgan Stanley Analyst forecast on CNTA
Sean LaamanMorgan Stanley
Morgan Stanley
$27
Buy
90.14%
Upside
Reiterated
05/19/25
Centessa Pharmaceuticals (CNTA) Receives a Buy from Morgan Stanley
BMO Capital Analyst forecast on CNTA
Kostas BiliourisBMO Capital
BMO Capital
$35
Buy
146.48%
Upside
Reiterated
05/15/25
Reiterating Our Conviction in CNTA Multi-Billion Dollar Orexin Franchise
Chardan Capital Analyst forecast on CNTA
Rudy LiChardan Capital
Chardan Capital
$30
Buy
111.27%
Upside
Reiterated
05/14/25
Chardan Capital Reaffirms Their Buy Rating on Centessa Pharmaceuticals (CNTA)
B.Riley Financial Analyst forecast on CNTA
Mayank MamtaniB.Riley Financial
B.Riley Financial
$33
Buy
132.39%
Upside
Reiterated
01/21/25
Analysts Conflicted on These Healthcare Names: Ironwood Pharma (NASDAQ: IRWD) and Centessa Pharmaceuticals (NASDAQ: CNTA)
Guggenheim
$24$28
Buy
97.18%
Upside
Reiterated
11/15/24
Centessa price target raised to $28 from $24 at GuggenheimCentessa price target raised to $28 from $24 at Guggenheim
Oppenheimer
$24
Buy
69.01%
Upside
Reiterated
09/26/24
Oppenheimer reiterates Outperform Rating on Centessa Pharmaceuticals (CNTA)Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $24.00 price target on Centessa Pharmaceuticals (NASDAQ: CNTA).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on CNTA
Stacy KuTD Cowen
TD Cowen
Buy
Reiterated
06/17/25
TD Cowen Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA)
Leerink Partners Analyst forecast on CNTA
David RisingerLeerink Partners
Leerink Partners
$36
Buy
153.52%
Upside
Reiterated
06/09/25
Leerink Partners Remains a Buy on Centessa Pharmaceuticals (CNTA)
Jefferies Analyst forecast on CNTA
Kelly ShiJefferies
Jefferies
$27
Buy
90.14%
Upside
Reiterated
06/04/25
Centessa Pharmaceuticals: Promising Orexin Drug Pipeline and Strong Market Potential Drive Buy Rating
Needham Analyst forecast on CNTA
Ami FadiaNeedham
Needham
$35
Buy
146.48%
Upside
Initiated
05/28/25
Positive Outlook on Centessa Pharmaceuticals Driven by ORX750's Promising Potential and Market Growth
Piper Sandler Analyst forecast on CNTA
Biren AminPiper Sandler
Piper Sandler
$38
Buy
167.61%
Upside
Reiterated
05/20/25
Centessa Pharmaceuticals (CNTA) Receives a Buy from Piper Sandler
Morgan Stanley Analyst forecast on CNTA
Sean LaamanMorgan Stanley
Morgan Stanley
$27
Buy
90.14%
Upside
Reiterated
05/19/25
Centessa Pharmaceuticals (CNTA) Receives a Buy from Morgan Stanley
BMO Capital Analyst forecast on CNTA
Kostas BiliourisBMO Capital
BMO Capital
$35
Buy
146.48%
Upside
Reiterated
05/15/25
Reiterating Our Conviction in CNTA Multi-Billion Dollar Orexin Franchise
Chardan Capital Analyst forecast on CNTA
Rudy LiChardan Capital
Chardan Capital
$30
Buy
111.27%
Upside
Reiterated
05/14/25
Chardan Capital Reaffirms Their Buy Rating on Centessa Pharmaceuticals (CNTA)
B.Riley Financial Analyst forecast on CNTA
Mayank MamtaniB.Riley Financial
B.Riley Financial
$33
Buy
132.39%
Upside
Reiterated
01/21/25
Analysts Conflicted on These Healthcare Names: Ironwood Pharma (NASDAQ: IRWD) and Centessa Pharmaceuticals (NASDAQ: CNTA)
Guggenheim
$24$28
Buy
97.18%
Upside
Reiterated
11/15/24
Centessa price target raised to $28 from $24 at GuggenheimCentessa price target raised to $28 from $24 at Guggenheim
Oppenheimer
$24
Buy
69.01%
Upside
Reiterated
09/26/24
Oppenheimer reiterates Outperform Rating on Centessa Pharmaceuticals (CNTA)Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $24.00 price target on Centessa Pharmaceuticals (NASDAQ: CNTA).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Centessa Pharmaceuticals

1 Month
xxx
Success Rate
14/21 ratings generated profit
67%
Average Return
+7.62%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +7.62% per trade.
3 Months
xxx
Success Rate
5/6 ratings generated profit
83%
Average Return
+20.87%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +20.87% per trade.
1 Year
Kelly ShiJefferies
Success Rate
5/6 ratings generated profit
83%
Average Return
+66.73%
reiterated a buy rating 24 days ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +66.73% per trade.
2 Years
xxx
Success Rate
5/6 ratings generated profit
83%
Average Return
+46.17%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +46.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CNTA Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
6
9
7
14
10
Buy
6
5
4
3
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
14
11
17
14
In the current month, CNTA has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CNTA average Analyst price target in the past 3 months is 32.57.
Each month's total comprises the sum of three months' worth of ratings.

CNTA Financial Forecast

CNTA Earnings Forecast

Next quarter’s earnings estimate for CNTA is -$0.33 with a range of -$0.37 to -$0.25. The previous quarter’s EPS was -$0.20. CNTA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year CNTA has Outperformed its overall industry.
Next quarter’s earnings estimate for CNTA is -$0.33 with a range of -$0.37 to -$0.25. The previous quarter’s EPS was -$0.20. CNTA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year CNTA has Outperformed its overall industry.

CNTA Sales Forecast

Next quarter’s sales forecast for CNTA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $15.06M. CNTA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CNTA has Outperformed its overall industry.
Next quarter’s sales forecast for CNTA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $15.06M. CNTA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CNTA has Outperformed its overall industry.

CNTA Stock Forecast FAQ

What is CNTA’s average 12-month price target, according to analysts?
Based on analyst ratings, Centessa Pharmaceuticals’s 12-month average price target is 32.57.
    What is CNTA’s upside potential, based on the analysts’ average price target?
    Centessa Pharmaceuticals has 129.37% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CNTA a Buy, Sell or Hold?
          Centessa Pharmaceuticals has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Centessa Pharmaceuticals’s price target?
            The average price target for Centessa Pharmaceuticals is 32.57. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $38.00 ,the lowest forecast is $27.00. The average price target represents 129.37% Increase from the current price of $14.2.
              What do analysts say about Centessa Pharmaceuticals?
              Centessa Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of CNTA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis